查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球分子诊断市场（至 2030 年）按产品和服务、测试类型、样本、技术和应用（感染疾病和癌症）划分
市场调查报告书
商品编码
1811751

全球分子诊断市场（至 2030 年）按产品和服务、测试类型、样本、技术和应用（感染疾病和癌症）划分

Molecular Diagnostics Market by Product & Service, Test Type, Sample, Technology, and Application (Infectious, Cancer ) - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 540 Pages | 订单完成后即时交付

价格

分子诊断市场预计将从 2025 年的约 194.8 亿美元成长到 2030 年的 307.4 亿美元，预测期内的复合年增长率为 9.6%。

分子诊断技术因其能够在分子和基因层面检测疾病的能力，在现代医学中发挥着至关重要的作用。这些技术具有高灵敏度和特异性，能够及早识别病原体和基因异常。持续的技术创新，例如更快的处理时间、自动化平台和改进的检测设计，大大提高了分子检测的可靠性和可及性。这些创新对于支持在各种医疗环境中进行大规模检测至关重要。

调查范围
调查年份 2024-2030
基准年 2024
预测期 2025-2030
单元 金额（美元）
部分 产品与服务、测试类型、样本类型、技术、应用、方法、临床应用、最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

此外，印度等国家的政府和私营部门正在采取倡议，提高公众意识并扩大诊断和治疗服务的可及性，预计这将在未来几年加速分子诊断的普及。

分子诊断市场-IMG1

按样本类型划分，血液、血清和血浆将在 2024 年占据市场主导地位。

这是因为这些样本类型在检测多种疾病（包括病毒感染疾病和肿瘤疾病）方面具有高灵敏度和特异性。它们在运输和储存过程中也保持稳定，使其成为集中式实验室和照护现场环境的理想选择。此外，个人化医疗的日益普及以及生物标记在临床决策中的日益广泛应用，正在推动血液分子检测的需求。这些优势预计将推动该领域持续强劲成长。

“从技术角度来看，DNA定序和次世代定序（NGS）领域预计将在预测期内实现最高增长。”

这种快速增长的动力源于其在检测基因突变、识别感染源和製定个人化治疗方案方面的广泛应用。此外，处理速度的提高和数据准确性的提升也推动了其在科学研究和临床领域的广泛应用。此外，NGS因其高通量能力和在全面基因组分析中的效用而备受关注。随着精准医疗的进步，对基于定序的诊断的需求预计将大幅增长。

预计亚太地区将成为预测期内成长最快的区域市场。

这一增长得益于新兴经济体医疗保健投资的不断增加、早期疾病检测意识提升以及先进诊断技术的日益普及。中国、印度和韩国等国家正在迅速改善其医疗保健基础设施和检测实验室能力。此外，旨在加强感染疾病监测和扩大分子检测管道的政府措施也促进了市场成长。此外，庞大的患者群体和对个人化医疗保健解决方案日益增长的需求进一步提升了该地区的成长潜力。

本报告调查了全球分子诊断市场，并提供了市场概况、影响市场成长的各种因素分析、技术和专利趋势、法律制度、案例研究、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章 市场概况

  • 市场动态
    • 驱动程式
    • 抑制因素
    • 机会
    • 任务
  • 定价分析
  • 专利分析
  • 价值链分析
  • 供应链分析
  • HS 编码
  • 生态系分析
  • 波特五力分析
  • 监管状况
  • 技术分析
  • 2025-2026年重要会议和活动
  • 影响客户业务的趋势/中断
  • 主要相关人员和采购标准
  • 投资金筹措场景
  • 案例研究分析
  • 人工智慧/生成式人工智慧对分子诊断市场的影响
  • 美国2025年关税

第六章分子诊断市场（按产品和服务）

  • 试剂和套件
  • 装置
  • 服务软体

第七章分子诊断市场（依测试类型）

  • 实验室筛检
  • POC 测试

第八章分子诊断市场（依样本类型）

  • 血液、血清、血浆
  • 尿
  • 其他的

第九章分子诊断市场（按技术）

  • 聚合酵素链锁反应
  • 恒温核酸增幅技术
  • DNA定序/次世代定序
  • 原位杂交
  • DNA微阵列
  • 其他的

第 10 章分子诊断市场（按应用）

  • 感染疾病诊断
    • 性行为感染传染病
    • 肝炎
    • 呼吸道感染疾病
    • 医院感染疾病
    • 媒介传播疾病
    • 其他的
  • 癌症筛检
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 摄护腺癌
    • 其他的
  • 基因检测
  • 其他的

第11章分子诊断市场（按技术）

  • 多重测试
  • 单重测试

第十二章分子诊断市场（依临床应用）

  • 诊断
  • 筛检

第 13 章 分子诊断市场（依最终使用者）

  • 诊断实验室
  • 医院和诊所
  • 其他的

第十四章分子诊断市场（按地区）

  • 北美洲
    • 宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 瑞士
    • 其他的
  • 亚太地区
    • 宏观经济展望
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲
    • 宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 宏观经济展望
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的

第十五章 竞争格局

  • 主要参与企业的策略/优势
  • 收益份额分析
  • 市占率分析
  • 公司评估矩阵：主要企业
  • 公司估值矩阵：Start-Ups/中小型企业
  • 估值和财务指标
  • 品牌/产品比较
  • 竞争场景

第十六章：公司简介

  • 主要企业
    • DANAHER CORPORATION
    • F. HOFFMANN-LA ROCHE LTD
    • ILLUMINA, INC.
    • HOLOGIC, INC.
    • BIOMERIEUX
    • ABBOTT LABORATORIES
    • THERMO FISHER SCIENTIFIC INC.
    • QIAGEN NV
    • REVVITY, INC.
    • MYRIAD GENETICS, INC.
    • SIEMENS HEALTHINEERS AG
  • 其他公司
    • BECTON, DICKINSON AND COMPANY (BD)
    • GRIFOLS, SA
    • QUIDELORTHO CORPORATION
    • DIASORIN SPA
    • EXACT SCIENCES CORPORATION
    • GENETIC SIGNATURES
    • AGILENT TECHNOLOGIES, INC.
    • MDXHEALTH
    • BIOCARTIS
    • MEDIGEN BIOTECHNOLOGY CORP.
    • VELA DIAGNOSTICS
    • AMOY DIAGNOSTICS CO., LTD.
    • BRUKER CORPORATION (ELITECHGROUP)
    • MOLBIO DIAGNOSTICS LIMITED
    • GENEOMBIOTECHNOLOGIES
    • SAVYON DIAGNOSTICS
    • UNIOGEN OY

第十七章 附录

Product Code: MD 2521

The molecular diagnostics market is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030 at a CAGR of 9.6% during the forecast period. Molecular diagnostics plays a vital role in modern healthcare by enabling disease detection at the molecular and genetic level. These technologies offer high sensitivity and specificity, allowing for the early identification of pathogens and genetic abnormalities. Continuous technological advancements, such as faster processing times, automated platforms, and improved assay designs, have significantly enhanced the reliability and accessibility of molecular tests. These innovations are significant in supporting large-scale testing efforts across diverse healthcare settings.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct & service, test type, sample type, technology, application, technique, clinical application, end user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Moreover, in countries like India, government and private sector initiatives contribute to increased public awareness and greater access to diagnostic and treatment services. Such efforts are expected to accelerate the adoption of molecular diagnostics in the coming years.

Molecular Diagnostics Market - IMG1

"By sample type, the blood, serum, and plasma segment dominated the molecular diagnostics market in 2024."

By sample type, the molecular diagnostics market is segmented into blood, serum & plasma; urine; and other sample types. The blood, serum, and plasma segment accounted for the largest share of the market in 2024. This is attributed to the high sensitivity and specificity these sample types offer in detecting a wide range of diseases, including viral infections and oncological conditions. Their stability during transportation and storage makes them ideal for centralized laboratories and point-of-care settings. Additionally, the growing adoption of personalized medicine and increased use of biomarkers in clinical decision-making fuel the demand for blood-based molecular testing. These advantages collectively position the segment for continued strong growth.

"By technology, the DNA sequencing & next-generation sequencing (NGS) segment is projected to achieve the highest growth during the forecast period."

By technology, the molecular diagnostics market is bifurcated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & next-generation sequencing (NGS) segment is projected to witness the highest growth during the forecast period. This surge is driven by their expanding use in detecting genetic mutations, identifying infectious agents, and guiding personalized treatment plans. The increasing turnaround time and data accuracy improvements have also broadened their adoption in research and clinical settings. Moreover, NGS is gaining traction due to its high-throughput capabilities and utility in comprehensive genomic profiling. As precision medicine continues to advance, the demand for sequencing-based diagnostics is set to rise significantly.

"Asia Pacific is projected to be the fastest-growing regional market during the forecast period."

The market for molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to witness the highest growth in the global molecular diagnostics market during the forecast period. This growth is supported by the rising healthcare investments, growing awareness of early disease detection, and increasing adoption of advanced diagnostic technologies across emerging economies. Countries such as China, India, and South Korea are experiencing rapid improvements in healthcare infrastructure and laboratory capacity. In addition, government initiatives aimed at strengthening infectious disease surveillance and expanding access to molecular testing are contributing to market growth. The large patient population and rising demand for personalized healthcare solutions further reinforce the region's growth potential.

Break-up of primary participant profiles in the molecular diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 -30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, Director-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa - 4%

The key players in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott Laboratories (US), bioMerieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services), test type (lab tests and PoC tests), sample type (blood, serum & plasma; urine; and other sample types), technology (polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies), application {infectious disease diagnostics [hepatitis (hepatitis B, hepatitis C & other hepatitis diseases), sexually transmitted diseases (HIV, CT/NG, HPV, syphilis, & other sexually transmitted diseases), respiratory infectious diseases (tuberculosis, influenza, pharyngitis, & other respiratory infectious diseases), hospital-acquired infections, vector-borne diseases, and other infectious diseases], oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancers), genetic testing and other applications}, technique (multiplex testing and singleplex testing), clinical application (diagnostic and screening), end user (hospitals & clinics, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular diagnostics market. A thorough analysis of the key industry players provides insights into their business overview, solutions, key strategies, acquisitions, and agreements. This report also covers a competitive analysis of upcoming startups in the molecular diagnostics market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report will help stakeholders understand the market pulse, providing information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers [Increasing prevalence of infectious diseases and cancer, growing R&D funding, surge in technological advancements in molecular diagnostics, and rising use of point-of-care (PoC) diagnostic tests], opportunities (Growing significance of companion diagnostics and increasing growth opportunities in emerging economies), restraints (Inadequate reimbursements and high cost of molecular diagnostic instruments), and challenges (Changing regulatory landscape, operational barriers and labor shortage, and introduction of alternative technologies) influencing the growth of the molecular diagnostics market.
  • Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market
  • Market Development: Comprehensive information about lucrative markets across varied regions
  • Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the molecular diagnostics market
  • Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMerieux (France), and Hologic, Inc. (US)

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 REGIONAL SCOPE
  • 1.4 INCLUSIONS & EXCLUSIONS
  • 1.5 YEARS CONSIDERED
  • 1.6 CURRENCY CONSIDERED
  • 1.7 KEY STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary sources
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
      • 2.2.1.2 Approach 2: Presentation of companies and primary interviews
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projections
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ASSESSMENT
  • 2.5 RESEARCH ASSUMPTIONS
    • 2.5.1 PARAMETRIC ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
  • 4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030
  • 4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030
  • 4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030
  • 4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030
  • 4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030
  • 4.7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2025 VS. 2030
  • 4.8 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030
  • 4.9 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030
  • 4.10 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of infectious diseases and cancer
      • 5.2.1.2 Growing R&D funding
      • 5.2.1.3 Surge in technological advancements
      • 5.2.1.4 Rising use of point-of-care diagnostic tests
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Inadequate reimbursements
      • 5.2.2.2 High cost of molecular diagnostic instruments
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing significance of companion diagnostics
      • 5.2.3.2 Increasing growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape
      • 5.2.4.2 Operational barriers and labor shortage
      • 5.2.4.3 Introduction of alternative technologies
  • 5.3 PRICING ANALYSIS
    • 5.3.1 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS
    • 5.3.2 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER
    • 5.3.3 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION
  • 5.4 PATENT ANALYSIS
    • 5.4.1 LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 HS CODES
    • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
    • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
  • 5.8 ECOSYSTEM ANALYSIS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT FROM NEW ENTRANTS
    • 5.9.2 THREAT FROM SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY FRAMEWORK
      • 5.10.1.1 North America
        • 5.10.1.1.1 US
        • 5.10.1.1.2 Canada
      • 5.10.1.2 Europe
        • 5.10.1.2.1 Germany
        • 5.10.1.2.2 UK
        • 5.10.1.2.3 France
        • 5.10.1.2.4 Italy
      • 5.10.1.3 Asia Pacific
        • 5.10.1.3.1 China
        • 5.10.1.3.2 Japan
        • 5.10.1.3.3 India
      • 5.10.1.4 Latin America
        • 5.10.1.4.1 Brazil
        • 5.10.1.4.2 Mexico
      • 5.10.1.5 Middle East
        • 5.10.1.5.1 Africa
    • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 TECHNOLOGY ANALYSIS
    • 5.11.1 KEY TECHNOLOGIES
      • 5.11.1.1 Polymerase chain reaction
    • 5.11.2 COMPLEMENTARY TECHNOLOGIES
      • 5.11.2.1 Microarrays
    • 5.11.3 ADJACENT TECHNOLOGIES
      • 5.11.3.1 Next-generation sequencing
  • 5.12 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
  • 5.15 INVESTMENT AND FUNDING SCENARIO
  • 5.16 CASE STUDY ANALYSIS
    • 5.16.1 CASE STUDY 1: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
    • 5.16.2 CASE STUDY 2: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS AND BED MANAGEMENT
    • 5.16.3 CASE STUDY 3: RAPID PCR TESTING STREAMLINED EMERGENCY CARE AND SURGICAL RESOURCE MANAGEMENT IN GERMAN HOSPITAL
  • 5.17 IMPACT OF AI/GENERATIVE AI ON MOLECULAR DIAGNOSTICS MARKET
    • 5.17.1 INTRODUCTION
    • 5.17.2 MARKET POTENTIAL OF AI
      • 5.17.2.1 Key use cases
    • 5.17.3 IMPLEMENTATION OF AI BY KEY COMPANIES
    • 5.17.4 FUTURE OF AI IN MOLECULAR DIAGNOSTICS MARKET
  • 5.18 US 2025 TARIFF
    • 5.18.1 INTRODUCTION
    • 5.18.2 KEY TARIFF RATES
    • 5.18.3 PRICE IMPACT ANALYSIS
    • 5.18.4 IMPACT ON REGION
      • 5.18.4.1 North America
      • 5.18.4.2 Europe
      • 5.18.4.3 Asia Pacific
    • 5.18.5 IMPACT ON END-USE INDUSTRIES
      • 5.18.5.1 Hospitals & clinics
      • 5.18.5.2 Diagnostic laboratories

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
  • 6.2 REAGENTS & KITS
    • 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION TO PROPEL MARKET
  • 6.3 INSTRUMENTS
    • 6.3.1 RISING NEED FOR QUICK AND ACCURATE TEST RESULTS TO BOOST MARKET
  • 6.4 SERVICES & SOFTWARE
    • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
  • 7.2 LAB TESTS
    • 7.2.1 INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET
  • 7.3 POC TESTS
    • 7.3.1 INCREASED INVESTMENT BY PUBLIC HEALTH AGENCIES AND GOVERNMENTS TO BOOST MARKET

8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 8.1 INTRODUCTION
  • 8.2 BLOOD, SERUM, AND PLASMA
    • 8.2.1 INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET
  • 8.3 URINE
    • 8.3.1 NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET
  • 8.4 OTHER SAMPLE TYPES

9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 9.1 INTRODUCTION
  • 9.2 POLYMERASE CHAIN REACTION
    • 9.2.1 RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH
  • 9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • 9.3.1 NEED FOR PROMPT DIAGNOSIS TO STIMULATE GROWTH
  • 9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    • 9.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • 9.5 IN SITU HYBRIDIZATION
    • 9.5.1 RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES AND GENE MAPPING TO BOOST MARKET
  • 9.6 DNA MICROARRAYS
    • 9.6.1 SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET
  • 9.7 OTHER TECHNOLOGIES

10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 INFECTIOUS DISEASE DIAGNOSTICS
    • 10.2.1 SEXUALLY TRANSMITTED DISEASES
      • 10.2.1.1 CT/NG
        • 10.2.1.1.1 Growing development of novel assays to boost market
      • 10.2.1.2 HIV
        • 10.2.1.2.1 Increasing blood transfusions and blood donations to propel market
      • 10.2.1.3 HPV
        • 10.2.1.3.1 Rising cases of cervical cancer to augment growth
      • 10.2.1.4 Syphilis
        • 10.2.1.4.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
      • 10.2.1.5 Other sexually transmitted diseases
    • 10.2.2 HEPATITIS
      • 10.2.2.1 Hepatitis B
        • 10.2.2.1.1 Need for ongoing management and monitoring of virus to drive market
      • 10.2.2.2 Hepatitis C
        • 10.2.2.2.1 Favorable government initiatives to support growth
      • 10.2.2.3 Other hepatitis diseases
    • 10.2.3 RESPIRATORY INFECTIOUS DISEASES
      • 10.2.3.1 Tuberculosis
        • 10.2.3.1.1 Rising focus on reducing tuberculosis deaths to fuel market
      • 10.2.3.2 Influenza
        • 10.2.3.2.1 Growing strains and subtypes to drive market
      • 10.2.3.3 Pharyngitis
        • 10.2.3.3.1 Need to differentiate between bacterial and viral infections to fuel growth
      • 10.2.3.4 Other respiratory infectious diseases
    • 10.2.4 HOSPITAL-ACQUIRED INFECTIONS
      • 10.2.4.1 Booming geriatric population to aid growth
    • 10.2.5 VECTOR-BORNE DISEASES
      • 10.2.5.1 Growing focus on disease surveillance to propel market
    • 10.2.6 OTHER INFECTIOUS DISEASES
  • 10.3 ONCOLOGY TESTING
    • 10.3.1 BREAST CANCER
      • 10.3.1.1 Increasing need to improve survival rates to support growth
    • 10.3.2 COLORECTAL CANCER
      • 10.3.2.1 Rising demand for biomarkers to fuel market
    • 10.3.3 LUNG CANCER
      • 10.3.3.1 Increasing use of predictive biomarkers to drive market
    • 10.3.4 PROSTATE CANCER
      • 10.3.4.1 Surge in advancements in genomic technologies to aid growth
    • 10.3.5 OTHER CANCER TYPES
  • 10.4 GENETIC TESTING
    • 10.4.1 GROWING IMPORTANCE OF DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET
  • 10.5 OTHER APPLICATIONS

11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

  • 11.1 INTRODUCTION
  • 11.2 MULTIPLEX TESTING
    • 11.2.1 RISING DEMAND FOR QUICK DIAGNOSIS TO PROMOTE GROWTH
  • 11.3 SINGLEPLEX TESTING
    • 11.3.1 NEED FOR AFFORDABLE TESTING TO AUGMENT GROWTH

12 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION

  • 12.1 INTRODUCTION
  • 12.2 DIAGNOSTIC
    • 12.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING AND TIMELY TREATMENT TO DRIVE MARKET
  • 12.3 SCREENING
    • 12.3.1 GROWING IMPORTANCE OF EARLY INFECTIOUS DISEASE SCREENING TO PROPEL MARKET EXPANSION

13 MOLECULAR DIAGNOSTICS MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 DIAGNOSTIC LABORATORIES
    • 13.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH
  • 13.3 HOSPITALS & CLINICS
    • 13.3.1 GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH
  • 13.4 OTHER END USERS

14 MOLECULAR DIAGNOSTICS MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 MACROECONOMIC OUTLOOK
    • 14.2.2 US
      • 14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market
    • 14.2.3 CANADA
      • 14.2.3.1 Growing focus on genomic research to fuel market
  • 14.3 EUROPE
    • 14.3.1 MACROECONOMIC OUTLOOK
    • 14.3.2 GERMANY
      • 14.3.2.1 Robust healthcare spending and increasing per capita disposable income to propel market
    • 14.3.3 UK
      • 14.3.3.1 Expanding community-based diagnostics to drive adoption of molecular diagnostics
    • 14.3.4 FRANCE
      • 14.3.4.1 Rising R&D expenditure for product launches and development of new technologies to augment growth
    • 14.3.5 ITALY
      • 14.3.5.1 Growing demographic shift toward elderly population to support market
    • 14.3.6 SPAIN
      • 14.3.6.1 Surge in demand for genetic and prenatal testing to aid growth
    • 14.3.7 RUSSIA
      • 14.3.7.1 Increasing access to quality healthcare to boost market growth
    • 14.3.8 SWITZERLAND
      • 14.3.8.1 Rising healthcare spending for new medications and therapies to drive market
    • 14.3.9 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 MACROECONOMIC OUTLOOK
    • 14.4.2 CHINA
      • 14.4.2.1 Growing public access to modern healthcare to drive market
    • 14.4.3 JAPAN
      • 14.4.3.1 Universal healthcare reimbursement policy to support market
    • 14.4.4 INDIA
      • 14.4.4.1 Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market
    • 14.4.5 AUSTRALIA
      • 14.4.5.1 Rising technological advancements to stimulate growth
    • 14.4.6 SOUTH KOREA
      • 14.4.6.1 Favorable government initiatives for promoting medical tourism to support growth
    • 14.4.7 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 MACROECONOMIC OUTLOOK
    • 14.5.2 BRAZIL
      • 14.5.2.1 Universal healthcare access to drive adoption in Brazil
    • 14.5.3 MEXICO
      • 14.5.3.1 Booming medical tourism industry to aid growth
    • 14.5.4 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 MACROECONOMIC OUTLOOK
    • 14.6.2 SAUDI ARABIA
      • 14.6.2.1 Rising government healthcare expenditure to boost market
    • 14.6.3 UAE
      • 14.6.3.1 Improvements in healthcare infrastructure to support growth
    • 14.6.4 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
  • 15.3 REVENUE SHARE ANALYSIS
  • 15.4 MARKET SHARE ANALYSIS, 2024
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Product & service footprint
      • 15.5.5.4 Sample type footprint
      • 15.5.5.5 Application footprint
  • 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 15.6.5.1 Detailed list of key startups/SMES
      • 15.6.5.2 Competitive benchmarking of startups/SMES
  • 15.7 COMPANY VALUATION & FINANCIAL METRICS
    • 15.7.1 FINANCIAL METRICS
    • 15.7.2 COMPANY VALUATION
  • 15.8 BRAND/PRODUCT COMPARISON
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT/SERVICES LAUNCHES AND APPROVALS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 DANAHER CORPORATION
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products/Services offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product/Service launches and approvals
        • 16.1.1.3.2 Deals
        • 16.1.1.3.3 Expansions
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Right to win
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses and competitive threats
    • 16.1.2 F. HOFFMANN-LA ROCHE LTD
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products/Services offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product/Service launches and approvals
        • 16.1.2.3.2 Deals
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Right to win
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses and competitive threats
    • 16.1.3 ILLUMINA, INC.
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products/Services offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product/Service launches and approvals
        • 16.1.3.3.2 Deals
        • 16.1.3.3.3 Expansions
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Right to win
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses and competitive threats
    • 16.1.4 HOLOGIC, INC.
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products/Services offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product/Service launches and approvals
        • 16.1.4.3.2 Deals
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Right to win
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses and competitive threats
    • 16.1.5 BIOMERIEUX
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products/Services offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product/Service launches and approvals
        • 16.1.5.3.2 Deals
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Right to win
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses and competitive threats
    • 16.1.6 ABBOTT LABORATORIES
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products/Services offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Product/Service launches and approvals
        • 16.1.6.3.2 Deals
    • 16.1.7 THERMO FISHER SCIENTIFIC INC.
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products/Services offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Product/Service launches and approvals
        • 16.1.7.3.2 Deals
    • 16.1.8 QIAGEN N.V.
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products/Services offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Product/Service launches and approvals
        • 16.1.8.3.2 Deals
        • 16.1.8.3.3 Expansions
    • 16.1.9 REVVITY, INC.
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products/Services offered
    • 16.1.10 MYRIAD GENETICS, INC.
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products/Services offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product/Service launches and approvals
        • 16.1.10.3.2 Deals
    • 16.1.11 SIEMENS HEALTHINEERS AG
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products/Services offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product/Service launches and approvals
        • 16.1.11.3.2 Deals
        • 16.1.11.3.3 Expansions
  • 16.2 OTHER PLAYERS
    • 16.2.1 BECTON, DICKINSON AND COMPANY (BD)
    • 16.2.2 GRIFOLS, S.A.
    • 16.2.3 QUIDELORTHO CORPORATION
    • 16.2.4 DIASORIN S.P.A.
    • 16.2.5 EXACT SCIENCES CORPORATION
    • 16.2.6 GENETIC SIGNATURES
    • 16.2.7 AGILENT TECHNOLOGIES, INC.
    • 16.2.8 MDXHEALTH
    • 16.2.9 BIOCARTIS
    • 16.2.10 MEDIGEN BIOTECHNOLOGY CORP.
    • 16.2.11 VELA DIAGNOSTICS
    • 16.2.12 AMOY DIAGNOSTICS CO., LTD.
    • 16.2.13 BRUKER CORPORATION (ELITECHGROUP)
    • 16.2.14 MOLBIO DIAGNOSTICS LIMITED
    • 16.2.15 GENEOMBIOTECHNOLOGIES
    • 16.2.16 SAVYON DIAGNOSTICS
    • 16.2.17 UNIOGEN OY

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 MOLECULAR DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 2 MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
  • TABLE 4 NUMBER OF CANCER PATIENTS WORLDWIDE, BY REGION, 2022 VS. 2035 VS. 2045
  • TABLE 5 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, 2023-2025 (USD)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER, 2023-2025 (USD)
  • TABLE 7 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025 (USD)
  • TABLE 8 LIST OF MAJOR PATENTS, 2022-2024
  • TABLE 9 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 10 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 11 MOLECULAR DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 12 IMPACT OF PORTER'S FORCES ON MOLECULAR DIAGNOSTICS MARKET
  • TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE
  • TABLE 14 TIME, COST, AND COMPLEXITY OF DEVICE REGISTRATION PROCESS IN JAPAN
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 MOLECULAR DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 22 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 23 RECIPROCAL TARIFF RATES ADJUSTED BY US
  • TABLE 24 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 25 KEY REAGENTS AND KITS AVAILABLE IN MARKET
  • TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 27 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 28 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 30 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 31 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 32 KEY INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 38 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 39 KEY SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE
  • TABLE 40 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 41 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 44 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 45 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 46 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 47 KEY LABORATORY TESTING INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 49 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 52 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 53 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 54 KEY POC TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 55 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 59 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 60 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 61 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 62 KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET
  • TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 64 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 67 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 68 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 69 KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET
  • TABLE 70 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 74 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 75 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 76 OTHER SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET
  • TABLE 77 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 78 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 81 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 82 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 83 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 84 KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 85 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 87 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 88 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 89 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 90 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 91 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 92 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 93 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 94 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 98 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 99 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 100 KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 101 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 102 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 103 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 106 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 107 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 108 KEY IN SITU HYBRIDIZATION PRODUCTS AVAILABLE IN MARKET
  • TABLE 109 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 110 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 114 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 115 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 116 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET
  • TABLE 117 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 118 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 119 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 123 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 124 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 125 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 126 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 129 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 130 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 131 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 132 KEY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 133 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 134 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 136 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 138 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 139 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 140 MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 141 MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 146 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 147 KEY CT/NG MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 148 MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET CT/NG, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 153 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 154 KEY HIV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 155 MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 156 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 158 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HIV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 159 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 160 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 161 KEY HPV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 162 MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 163 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HPV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 166 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 168 KEY SYPHILIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 169 MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 170 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 171 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 173 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 174 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 175 OTHER SEXUALLY TRANSMITTED DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 176 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 177 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 178 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 181 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 182 KEY HEPATITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 183 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 184 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 185 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 188 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 189 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 190 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 191 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 192 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 194 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 195 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 196 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 197 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 198 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 199 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 200 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 201 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 202 MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 203 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 204 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 206 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 207 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 208 MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 209 MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 210 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 211 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 213 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 214 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 215 KEY TUBERCULOSIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 216 MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 217 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 218 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 220 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 221 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 222 GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023-2030 (MILLIONS)
  • TABLE 223 KEY INFLUENZA MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 224 MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 225 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 226 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 228 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 229 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 230 KEY PHARYNGITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 231 MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 232 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 233 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 235 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 236 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 237 OTHER RESPIRATORY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 238 MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 239 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 240 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 242 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 243 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 244 KEY HOSPITAL-ACQUIRED INFECTION-BASED MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 245 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 246 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 247 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 248 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 249 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 250 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 251 KEY VECTOR-BORNE DISEASES DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 252 MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 253 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 254 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 255 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 256 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 257 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 258 GLOBAL CASES OF ACTIVE SYPHILIS IN AGE GROUP FROM 15 TO 49 YEARS, 2016-2022 (THOUSANDS)
  • TABLE 259 OTHER INFECTIOUS DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 260 MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 261 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 262 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 263 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 264 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 265 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 266 KEY ONCOLOGY TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 267 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 268 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 269 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 270 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 271 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 272 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 273 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 274 BREAST CANCER INCIDENCE, BY REGION, 2022 VS. 2030
  • TABLE 275 MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 276 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 277 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 278 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 279 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 281 COLORECTAL CANCER INCIDENCE, BY REGION, 2022 VS. 2030
  • TABLE 282 MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 283 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 284 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 285 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 286 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 287 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 288 LUNG CANCER INCIDENCE, BY REGION, 2022 VS. 2030
  • TABLE 289 MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 290 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 291 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 292 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 293 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 294 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 295 PROSTATE CANCER INCIDENCE, BY REGION, 2022 VS. 2030
  • TABLE 296 MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 297 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 298 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 299 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 300 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 301 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 302 GLOBAL INCIDENCE OF OTHER CANCER TYPES, 2022 VS. 2030
  • TABLE 303 MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 304 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 305 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 306 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 307 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 308 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 309 KEY GENETIC TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 310 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 311 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 312 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 314 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 315 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 316 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 317 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 318 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 320 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 321 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 322 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023-2030 (USD MILLION)
  • TABLE 323 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 324 MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 325 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 326 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 327 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 328 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 329 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 330 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 331 MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 332 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 333 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 334 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 335 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 336 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 337 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 338 KEY DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
  • TABLE 339 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 340 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 341 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 342 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 343 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 344 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 345 KEY SCREENING PRODUCTS AVAILABLE IN MARKET
  • TABLE 346 MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 347 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 348 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 349 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 350 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 352 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 353 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 354 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 355 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 356 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 357 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 358 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 359 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 360 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 361 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 362 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 363 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 364 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 365 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 366 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 367 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 368 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 369 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 370 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 371 PROJECTED CANCER CASES, BY COUNTRY, 2030
  • TABLE 372 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 373 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 374 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 375 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 376 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 377 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 378 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 379 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 380 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 381 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 382 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 383 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 384 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 385 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 386 US: CANCER CASES AND MORTALITY, BY CANCER TYPE, 2022 VS. 2030
  • TABLE 387 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 388 US: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 389 US: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 390 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 391 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 392 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 393 US: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 394 US: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 395 US: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 396 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 397 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 398 CANADA: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 399 CANADA: FIVE COMMON CANCER TYPES AND DEATH PERCENTAGE
  • TABLE 400 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 401 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 402 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 403 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 404 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 405 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 406 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 407 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 408 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 409 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 410 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 411 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 412 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 413 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 414 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 415 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 416 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 417 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 418 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 419 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 420 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 421 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 422 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 423 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 424 GERMANY: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 425 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 426 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 427 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 428 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 429 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 430 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 431 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 432 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 433 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 434 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 435 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 436 UK: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 437 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 438 UK: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 439 UK: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 440 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 441 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 442 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 443 UK: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 444 UK: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 445 UK: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 446 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 447 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 448 FRANCE: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 449 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 450 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 451 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 452 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 453 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 454 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 455 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 456 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 457 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 458 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 459 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 460 ITALY: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 461 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 462 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 463 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 464 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 465 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 466 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 467 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 468 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 469 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 470 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 471 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 472 SPAIN: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 473 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 474 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 475 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 476 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 477 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 478 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 479 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 480 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 481 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 482 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 483 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 484 RUSSIA: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 485 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 486 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 487 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 488 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 489 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 490 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 491 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 492 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 493 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 494 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 495 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 496 SWITZERLAND: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 497 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 498 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 499 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 500 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 501 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 502 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 503 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 504 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 505 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 506 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 507 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 508 REST OF EUROPE: PROJECTED CANCER CASES, BY COUNTRY, 2030
  • TABLE 509 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 510 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 511 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 512 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 513 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 514 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 515 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 516 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 517 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 518 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 519 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 520 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 521 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 522 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 523 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 524 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 525 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 526 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 527 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 528 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 529 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 530 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 531 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 532 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 533 CHINA: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 534 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 535 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 536 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 537 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 538 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 539 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 540 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 541 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 542 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 543 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 544 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 545 JAPAN: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 546 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 547 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 548 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 549 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 550 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 551 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 552 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 553 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 554 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 555 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 556 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 557 INDIA: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 558 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 559 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 560 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 561 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 562 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 563 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 564 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 565 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 566 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 567 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 568 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 569 AUSTRALIA: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 570 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 571 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 572 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 573 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 574 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 575 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 576 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 577 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 578 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 579 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 580 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 581 SOUTH KOREA: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 582 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 583 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 584 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 585 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 586 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 587 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 588 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 589 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 590 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 591 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 592 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 593 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 594 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 595 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 596 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 597 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 598 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 599 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 600 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 601 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 602 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 603 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 604 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 605 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 606 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 607 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 608 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 609 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 610 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 611 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 612 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 613 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 614 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 615 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 616 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 617 BRAZIL: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 618 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 619 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 620 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 621 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 622 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 623 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 624 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 625 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 626 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 627 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 628 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 629 MEXICO: PROJECTED CANCER CASES, BY TYPE, 2030
  • TABLE 630 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 631 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 632 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 633 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 634 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 635 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 636 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 637 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 638 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 639 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 640 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 641 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 642 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 643 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 644 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 645 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 646 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 647 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 648 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 649 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 650 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 651 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 652 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 653 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 654 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 655 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 656 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 657 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 658 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 659 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 660 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 661 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 662 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 663 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 664 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 665 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 666 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 667 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 668 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 669 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 670 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 671 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 672 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 673 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 674 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 675 SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 676 UAE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 677 UAE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 678 UAE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 679 UAE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 680 UAE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 681 UAE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 682 UAE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 683 UAE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 684 UAE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 685 UAE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 686 UAE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 687 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
  • TABLE 688 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023-2030 (USD MILLION)
  • TABLE 689 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
  • TABLE 690 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 691 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 692 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 693 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 694 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 695 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 696 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 697 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 698 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021-JULY 2025
  • TABLE 699 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 700 MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 701 MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 702 MOLECULAR DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT
  • TABLE 703 MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT
  • TABLE 704 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 705 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 706 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 707 MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 708 MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021-JULY 2025
  • TABLE 709 MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021- JULY 2025
  • TABLE 710 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 711 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 712 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 713 DANAHER CORPORATION: DEALS, JANUARY 2021-JULY 2025
  • TABLE 714 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-JULY 2025
  • TABLE 715 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 716 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 717 F. HOFFMANN-LA ROCHE LTD: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 718 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021-JULY 2025
  • TABLE 719 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 720 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 721 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 722 ILLUMINA, INC.: DEALS, JANUARY 2021- JULY 2025
  • TABLE 723 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021-JULY 2025
  • TABLE 724 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 725 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 726 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 727 HOLOGIC, INC.: DEALS, JANUARY 2021- JULY 2025
  • TABLE 728 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 729 BIOMERIEUX: PRODUCTS/SERVICES OFFERED
  • TABLE 730 BIOMERIEUX: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 731 BIOMERIEUX: DEALS, JANUARY 2021- JULY 2025
  • TABLE 732 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 733 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED
  • TABLE 734 ABBOTT LABORATORIES: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 735 ABBOTT LABORATORIES: DEALS, JANUARY 2021- JULY 2025
  • TABLE 736 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 737 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 738 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 739 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021- JULY 2025
  • TABLE 740 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 741 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
  • TABLE 742 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 743 QIAGEN N.V.: DEALS, JANUARY 2021- JULY 2025
  • TABLE 744 QIAGEN N.V.: EXPANSIONS, JANUARY 2021-JULY 2025
  • TABLE 745 REVVITY, INC.: COMPANY OVERVIEW
  • TABLE 746 REVVITY, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 747 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 748 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 749 MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 750 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021- JULY 2025
  • TABLE 751 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 752 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 753 SIEMENS HEALTHINEERS AG: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2025
  • TABLE 754 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021- JULY 2025
  • TABLE 755 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021- JULY 2025
  • TABLE 756 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
  • TABLE 757 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 758 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 759 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 760 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
  • TABLE 761 GENETIC SIGNATURES: COMPANY OVERVIEW
  • TABLE 762 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 763 MDXHEALTH: COMPANY OVERVIEW
  • TABLE 764 BIOCARTIS: COMPANY OVERVIEW
  • TABLE 765 MEDIGEN BIOTECHNOLOGY CORP.: COMPANY OVERVIEW
  • TABLE 766 VELA DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 767 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 768 BRUKER CORPORATION (ELITECHGROUP): COMPANY OVERVIEW
  • TABLE 769 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW
  • TABLE 770 GENEOMBIOTECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 771 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 772 UNIOGEN OY: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 RESEARCH DESIGN METHODOLOGY
  • FIGURE 2 KEY PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • FIGURE 9 MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
  • FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 19 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET
  • FIGURE 20 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 22 BLOOD, SERUM, AND PLASMA SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 23 POLYMERASE CHAIN REACTION SEGMENT TO ACHIEVE LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 24 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 25 MULTIPLEX TESTING SEGMENT TO ACCOUNT FOR SIGNIFICANT SHARE DURING FORECAST PERIOD
  • FIGURE 26 DIAGNOSTIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 27 DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET IN 2030
  • FIGURE 28 NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 29 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 30 INCIDENCE OF HIV, BY REGION, 2024
  • FIGURE 31 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES, JANUARY 2015-DECEMBER 2024
  • FIGURE 32 MOLECULAR DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 33 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 34 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 35 MOLECULAR DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 36 MOLECULAR DIAGNOSTICS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 38 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 39 NUMBER OF DEALS & TOTAL FUNDING, 2021-2025
  • FIGURE 40 MOLECULAR DIAGNOSTICS MARKET: KEY USE CASES
  • FIGURE 41 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 42 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS, 2022-2024 (USD MILLION)
  • FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 45 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 46 MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 47 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 48 EV/EBITDA OF KEY VENDORS
  • FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 50 BRAND/PRODUCT COMPARISON FOR MOLECULAR DIAGNOSTIC INSTRUMENTS
  • FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 54 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 55 BIOMERIEUX: COMPANY SNAPSHOT (2024)
  • FIGURE 56 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024)
  • FIGURE 57 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 QIAGEN N.V.: COMPANY SNAPSHOT (2024)
  • FIGURE 59 REVVITY, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 60 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 61 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)